News

New Jersey-based Wyeth has announced that the new data from phase-III clinical trials shows that investigational pneumococcal vaccine, Prevenar13, has the potential to provide coverage against the 13

Medivation has completed patient enrollment in the six-month, confirmatory, pivotal Phase-III trial of the investigational drug dimebon, in patients with mild-to-moderate Alzheimer’s disease. The pivotal Phase-III study enrolled

STAAR has announced that FDA has granted 510(k) clearance for Epiphany Injector System for use with the Affinity Collamer Three-Piece NTIOL and the Elastimide Silicone NTIOL. Epiphany has

Jubilant Organosys has announced that its Bangalore-based subsidiary, Jubilant Biosys has entered into a discovery and development collaboration with Endo Pharmaceuticals. Under the terms of the agreement, Jubilant

Pfizer has announced that data from two new mid-stage clinical studies of oral JAK-3 inhibitor, CP-690,550, showed statistically significant response, versus placebo for patients with rheumatoid arthritis (RA).

Watson has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market its guaifenesin pseudoephedrine HCI extended-release 600mg/60mg and 1200mg/120mg tablets prior to the

nCircle and Health Information Trust Alliance (HITRUST) have announced that nCircle has been selected as the provider of vulnerability and configuration assessments as a service for the HITRUST

PharmaSURVEYOR has announced the integration of their Advanced Drug Safety service with Microsoft HealthVault. The tool is designed to show users not only drug-drug interactions but also the

MonoSol Rx, the developers of PharmFilm technology and a drug delivery company has announced that the new drug application (NDA) for ondansetron orally dissolving film strip (ODFS) has